scispace - formally typeset
S

Sid E. O'Bryant

Researcher at University of North Texas Health Science Center

Publications -  223
Citations -  10553

Sid E. O'Bryant is an academic researcher from University of North Texas Health Science Center. The author has contributed to research in topics: Medicine & Disease. The author has an hindex of 41, co-authored 168 publications receiving 8123 citations. Previous affiliations of Sid E. O'Bryant include Universidad del Norte, Colombia & Texas Tech University Health Sciences Center.

Papers
More filters
Journal ArticleDOI

Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria.

TL;DR: An updated review of the literature and evidence on the definitions and lexicon, the limits, the natural history, the markers of progression, and the ethical consequence of detecting the disease at this asymptomatic stage of Alzheimer's disease are provided.
Journal ArticleDOI

Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease

Rebecca Sims, +487 more
- 01 Sep 2017 - 
TL;DR: Three new genome-wide significant nonsynonymous variants associated with Alzheimer's disease are observed, providing additional evidence that the microglia-mediated innate immune response contributes directly to the development of Alzheimer's Disease.
Journal ArticleDOI

Detecting Dementia With the Mini-Mental State Examination in Highly Educated Individuals

TL;DR: Older patients with a college education who present with complaints of cognitive decline and score less than 27 on the MMSE are at a greater risk of being diagnosed with dementia and should be referred for a comprehensive dementia evaluation, including formal neuropsychological testing.
Journal ArticleDOI

Staging dementia using Clinical Dementia Rating Scale Sum of Boxes scores: a Texas Alzheimer's research consortium study.

TL;DR: In this article, the authors investigated the effectiveness of CDR-SOB scores in staging dementia severity compared with the global CDR score, and they found that the increased range of values offered several advantages over the global score, including increased utility in tracking changes within and between stages of dementia severity.
Journal ArticleDOI

Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic.

TL;DR: This Review summarizes the efforts of an international working group that aimed to survey the current landscape of blood-based AD biomarkers and outlines operational steps for an effective academic–industry co-development pathway from identification and assay development to validation for clinical use.